A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

 

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

3Y0K DXpedition
Into Bouvet with 3Y0K: Wolfgang HB9RYZ Takes on the Challenge of Radio’s Rarest Frontier
December 5, 2025

Remote, icy, and battered by the South Atlantic, Bouvet Island is often called the most isolated place on Earth. This Norwegian territory, located roughly halfway between South Africa and Antarctica, has long captured the imagination of amateur radio operators because of its extreme inaccessibility and status as one of the rarest DXCC entities. In February…

Read More
personal branding
Personal Branding Now Drives B2B Success, Customer Trust, and Competitive Advantage
December 5, 2025

Personal branding has rapidly shifted from a “nice-to-have” to a strategic imperative in B2B marketing, reshaping how companies communicate, differentiate, and build trust. As industries evolve and professionals take on more dynamic, multi-stream careers, visibility and authenticity have become critical assets. Key findings from the Edelman + LinkedIn Thought Leadership Impact Report show that…

Read More
IT
Real-World IT Practices Are Streamlining AV Deployments and Raising the Bar for Consistency
December 4, 2025

For years, the AV industry has discussed the long-anticipated convergence with IT—but that shift is no longer theoretical. With cloud adoption accelerating, hybrid work normalizing, and organizations rebuilding digital infrastructure after years of rapid change, AV systems now sit squarely on the IT backbone. In fact, the majority of newly upgraded conference rooms require network-centric…

Read More
ROI
ROI Case Study
December 3, 2025

Denials are no longer a slow leak in the revenue cycle—they’re a fast-moving, rule-shifting game controlled by payers, and hospitals that don’t model denial patterns in real time end up budgeting around losses they could have prevented. PayerWatch’s four-digit, client-verified ROI in 2024 shows what happens when a hospital stops reacting claim by…

Read More